Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

A decision is expected in the fourth quarter of 2025.

Nutrition-tracking platform Healthify is banking on weight-loss drugs to boost growth, anticipating demand for these medicines to boom in India. The company is increasing its offerings to ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said ... are part of a wave of obesity medications known ...

CVS Health on Thursday said it will ... Wegovy on its formularies — or lists of covered drugs — making it the preferred GLP-1 drug for obesity. The move is part of a new partnership between ...

CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1 ...

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...